Congenital Heart DiseaseNCT00772135
Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients
A study testing sildenafil citrate in people with Congenital Heart Disease, run by Oslo University Hospital at 1 site in Norway.
Trial summary
The purpose of this study is to determine whether oral sildenafil citrate reduces the abnormal right ventricular pressure response during exercise in adolescent and adult patients with specific types of congenital heart defects. Read more about this study
- Who is it for?
- Ages 16 to 25 years
- Conditions the study is for
- Congenital Heart Disease
- What is being tested?
- sildenafil citrate
- Type of treatment
- Pill or oral medicine
- How many people
- 15 participants
- Where
- 1 siteNorway
- Study dates
- Sep 2008to Apr 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Exercise right ventricular systolic pressure of 45 mm Hg or above.
- Operated for atrial septal defect or ventricular septal defect or minimal defect not operated or minimal residual defect.
Who cannot join
- Acute infectious/febrile illness,
- Significant mental or physical disability preventing reliable exercise testing
Trial locations and contacts
1 site in 1 country.
Norway1 site, 1 recruiting
- Recruiting
Rikshospitalet University Hospital
Oslo, Oslo, 0027
Henrik Brun, MD, +4723074554, henrik.brun@rikshospitalet.no
per morten fredriksen, dr scient, +4723072277, per.morten.fredriksen@rikshospitalet.no
About this study
Official title: Pulmonary Hypertension in Adolescents and Adults With Congenital Heart Disease
The purpose of this study is to determine whether oral sildenafil citrate reduces the abnormal right ventricular pressure response during exercise in adolescent and adult patients with specific types of congenital heart defects.
Read the detailed description
13.3 Study design and protocol
13.3.1 Design: double-blind case-control cross-over study
13.3.2 Patients inclusion / exclusion criteria:
The study consists of 12-16 patients from the main study (see main protocol) who are selected by following criteria
- Abnormal right ventricular pressure response to exercise (cut-off 45 mmHg maximal RVSP during exercise)
- Informed consent to participation including use of sildenafil / placebo. The patients will be approximately one year older than during the initial study.
13.3.3 Examination protocol
The patients will be examined similarly twice with at least 12 hours and one night sleep between these activities to ensure drug washout. One hour before each study part, a pharmacy produced capsule (envelope coded and drawn in a random manner from a box) containing either sildenafil citrate 50 mg or placebo will be administered. In this manner each patient will be tested once with placebo use and once with sildenafil use respectively.
The participant is taken to a clinical exercise physiology laboratory for testing separated by a night's sleep and at least 12 hours.
Monitoring equipment is mounted during the period of drug absorbtion and distribution.
- One minute handgrip static exercise is performed as described with 80% of maximal strength applied. BP response is registered beat to beat.
- Pulmonary function is examined, including pulmonary volumes (single breath, technical description see below), and spirometry
- Cardiopulmonary exercise testing according to main protocol (see 3.8)
- Exercise echocardiography during supine bicycle exercise is performed as described in main protocol (see 3.7). Other monitoring during supine cycle exercise:
- ECG
- Diffusion capacity is monitored (intra breath, technical description below). For equipment calibration haemoglobin concentration is measured by fingertip blood sampling before and after cycle exercise.
- Cardiac output and peripheral oxygen saturation is continuously monitored by Task Force Monitor (see below)
- Pulmonary function testing is repeated
- Handgrip testing is repeated as in 1.
Difffusion capacity monitoring There are two ways of measuring diffusion capacity using SensorMedics V-max analyzing system (Yorba Linda, CA, USA) - intra breath and single breath.
Measurements of forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1 ratio (FEV1/FVC), peak expiratory flow (PEF), total lung capacity (TLC or VA), diffusion capacity for carbon monoxide (TLCO), adjusted diffusing capacity (TLCO/VA), residual volume (RV), capillary blood volume (Vc) and membrane conductance (Dm) are included in the analysis and will be performed according to European Respiratory Society standards.
Single breath The diffusion capacity is used to estimate the amount of gas travelling from lungs to the bloodstream across the membrane. In the process methane (CH4) is used in the concentration of 0.3 %, 0.3 % carbon monoxide (CO), 21 % oxygen (O2) and nitrogen (N2). In the estimation of TLCO several measurements are included; 1) the area of gas transportation between alveoli and the capillaries (A), 2) the wall thickness (membrane) between the alveoli and the erythrocytes (T), 3) the amount of haemoglobin available (Hb) and 4) the reaction rate of CO too Hb (θ) are determinants for the amount of CO that manage to diffuse across to the blood57.
In the process CH4 is used as a marker, as it does not diffuse across to the blood but become diluted. CH4 mixes with the residual volume in the lungs, and the degree of dilution is used to calculate alveoli volume. CO diffuses across to the blood in addition to become diluted. By measuring the amount of CO and CH4 in the expiration air compared to the inhaled gas, after a hold of breath in 8-10 seconds, we get an expression for the diffusion capacity in the lungs.
Figure 1: The single-breath method for TLCO Intra breath Intra breath reefers to the continuous real-time measurement of carbon monoxide uptake by the pulmonary capillary blood during a single breath maneuver. Intra breath maneuver may be performed during exercise.
The calibration procedure samples to set the span points to 0.3 % CO and 0.3 % CH4 (methane). The patient starts with normal breathing and is then instructed to exhale as much as possible - then inhale completely. After total inhalation the patient should exhale at a slow even flow until the computer end the test. The test window shows gas concentration versus time and volume versus time tracing in real time during the maneuver. The flow versus time curve is shown simultaneously. The collection interval used in the calculation of the TLCO is extending from 20 - 80 % of the exhaled volume (marked area in figure 2).
Figure 2. The intra breath method for TLCO
The patients need to practice this maneuver at rest before using it during exercise. The exhalation time is reduced during exercise, but the patients must try to exhale as slowly as they can in order for the analysis to be correct.
Cardiopulmonary monitoring and analysis When analysing changes in vascular resistances during exercise a measurement of pressure is only a part of the hemodynamic picture. According to Ohms law, blood flow measurement is necessary to conclude about the vascular resistances. For this purpose, a non-invasive cardiac stroke volume analyser based on thoracic impedance technique, will be used.(Task Force Monitor, CNS systems, product description enclosed) This equipment is validated for cardiac output monitoring as compared with thermodilution as gold standard. Combined with a beat to beat finger cuff system for measurement of blood pressure, this machine produces core circulatory parameters continuously. Autonomic nervous function (BP variation, HR variation) and baroreflex sensitivity is also analysed.
Continuous measurement of peripheral oxygen saturation is registered with Masimo SET pulse oximeters.
13.4 Statistics
Responses with and without sildenafil will be compared within same individual. For parameters affected by calibration differences in machinery from test 1 to 2 delta values will be compared.
Power analysis:
Data from the main study allow estimations of anticipated results and statistical power. If the average of maximal RVSP during exercise in our group is 50 mmHg and sildenafil causes a 20% decrease in average to 40 mmHg (SD 10.0) a sample size of 13 patients leads to statistical power of 81.7% with 5% confidence level (calculation: DSS research 10.7.2008, http://www.dssresearch.com/toolkit/spcalc/power_a2.asp
- Conditions
- Congenital Heart Disease
- Being tested
- sildenafil citrate
- Keywords
- pulmonary hypertension, congenital heart defects, exercise, phosphodiesterase inhibitors, Exercise induced pulmonary arterial hypertensive response in congenital heart disease
- Medical subject headings
- Heart Defects, Congenital, Hypertension, Pulmonary, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sildenafil citrateDrug
capsule of 50 mg , 90 minutes before exercise study
What is being measured
The primary outcome is the main question the study is designed to answer.
Right ventricular pressure as measured by max velocity of tricuspid valve regurgitation
Measured: baseline and max exercise
Secondary outcomes (2)
DLco (lung diffusion test)
Measured: baseline and max exercise
cardiac output
Measured: baseline and max exercise
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2008 (estimated)
- Study startSep 2008
- Primary completionFeb 2009 (estimated)
- Study completionApr 2009 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Congenital Heart DiseaseStudies of the same condition, open and under way.
- More trials run by Oslo University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oslo University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Norwegian Foundation for Health and Rehabilitation, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00772135
- Sponsor's protocol ID
- RH 2008 HR 2006 / 2 / 0012 TM
- Other IDs
- 2006 / 2 / 0012
- Status last verified
- Oct 2008
- First submitted
- 14 Oct 2008
- Last updated
- 15 Oct 2008
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pulmonary Hypertension in Adolescents and Adults With Congenital Heart Disease
- ClinicalTrials.gov ID
- NCT00772135
- Acronym / sponsor ID
- RH 2008 HR 2006 / 2 / 0012 TM
- Conditions
- Congenital Heart Disease
- Keywords
- pulmonary hypertension, congenital heart defects, exercise, phosphodiesterase inhibitors, Exercise induced pulmonary arterial hypertensive response in congenital heart disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Oslo University HospitalUniversity, hospital or other
- Collaborators
- Norwegian Foundation for Health and Rehabilitation, Pfizer
- Study start
- Sep 2008
- Primary completion
- Feb 2009 (estimated)
- Study completion
- Apr 2009 (estimated)
- First posted
- 15 Oct 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether oral sildenafil citrate reduces the abnormal right ventricular pressure response during exercise in adolescent and adult patients with specific types of congenital heart defects.
Detailed description
13.3 Study design and protocol
13.3.1 Design: double-blind case-control cross-over study
13.3.2 Patients inclusion / exclusion criteria:
The study consists of 12-16 patients from the main study (see main protocol) who are selected by following criteria
- Abnormal right ventricular pressure response to exercise (cut-off 45 mmHg maximal RVSP during exercise)
- Informed consent to participation including use of sildenafil / placebo. The patients will be approximately one year older than during the initial study.
13.3.3 Examination protocol
The patients will be examined similarly twice with at least 12 hours and one night sleep between these activities to ensure drug washout. One hour before each study part, a pharmacy produced capsule (envelope coded and drawn in a random manner from a box) containing either sildenafil citrate 50 mg or placebo will be administered. In this manner each patient will be tested once with placebo use and once with sildenafil use respectively.
The participant is taken to a clinical exercise physiology laboratory for testing separated by a night's sleep and at least 12 hours.
Monitoring equipment is mounted during the period of drug absorbtion and distribution.
- One minute handgrip static exercise is performed as described with 80% of maximal strength applied. BP response is registered beat to beat.
- Pulmonary function is examined, including pulmonary volumes (single breath, technical description see below), and spirometry
- Cardiopulmonary exercise testing according to main protocol (see 3.8)
- Exercise echocardiography during supine bicycle exercise is performed as described in main protocol (see 3.7). Other monitoring during supine cycle exercise:
- ECG
- Diffusion capacity is monitored (intra breath, technical description below). For equipment calibration haemoglobin concentration is measured by fingertip blood sampling before and after cycle exercise.
- Cardiac output and peripheral oxygen saturation is continuously monitored by Task Force Monitor (see below)
- Pulmonary function testing is repeated
- Handgrip testing is repeated as in 1.
Difffusion capacity monitoring There are two ways of measuring diffusion capacity using SensorMedics V-max analyzing system (Yorba Linda, CA, USA) - intra breath and single breath.
Measurements of forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1 ratio (FEV1/FVC), peak expiratory flow (PEF), total lung capacity (TLC or VA), diffusion capacity for carbon monoxide (TLCO), adjusted diffusing capacity (TLCO/VA), residual volume (RV), capillary blood volume (Vc) and membrane conductance (Dm) are included in the analysis and will be performed according to European Respiratory Society standards.
Single breath The diffusion capacity is used to estimate the amount of gas travelling from lungs to the bloodstream across the membrane. In the process methane (CH4) is used in the concentration of 0.3 %, 0.3 % carbon monoxide (CO), 21 % oxygen (O2) and nitrogen (N2). In the estimation of TLCO several measurements are included; 1) the area of gas transportation between alveoli and the capillaries (A), 2) the wall thickness (membrane) between the alveoli and the erythrocytes (T), 3) the amount of haemoglobin available (Hb) and 4) the reaction rate of CO too Hb (θ) are determinants for the amount of CO that manage to diffuse across to the blood57.
In the process CH4 is used as a marker, as it does not diffuse across to the blood but become diluted. CH4 mixes with the residual volume in the lungs, and the degree of dilution is used to calculate alveoli volume. CO diffuses across to the blood in addition to become diluted. By measuring the amount of CO and CH4 in the expiration air compared to the inhaled gas, after a hold of breath in 8-10 seconds, we get an expression for the diffusion capacity in the lungs.
Figure 1: The single-breath method for TLCO Intra breath Intra breath reefers to the continuous real-time measurement of carbon monoxide uptake by the pulmonary capillary blood during a single breath maneuver. Intra breath maneuver may be performed during exercise.
The calibration procedure samples to set the span points to 0.3 % CO and 0.3 % CH4 (methane). The patient starts with normal breathing and is then instructed to exhale as much as possible - then inhale completely. After total inhalation the patient should exhale at a slow even flow until the computer end the test. The test window shows gas concentration versus time and volume versus time tracing in real time during the maneuver. The flow versus time curve is shown simultaneously. The collection interval used in the calculation of the TLCO is extending from 20 - 80 % of the exhaled volume (marked area in figure 2).
Figure 2. The intra breath method for TLCO
The patients need to practice this maneuver at rest before using it during exercise. The exhalation time is reduced during exercise, but the patients must try to exhale as slowly as they can in order for the analysis to be correct.
Cardiopulmonary monitoring and analysis When analysing changes in vascular resistances during exercise a measurement of pressure is only a part of the hemodynamic picture. According to Ohms law, blood flow measurement is necessary to conclude about the vascular resistances. For this purpose, a non-invasive cardiac stroke volume analyser based on thoracic impedance technique, will be used.(Task Force Monitor, CNS systems, product description enclosed) This equipment is validated for cardiac output monitoring as compared with thermodilution as gold standard. Combined with a beat to beat finger cuff system for measurement of blood pressure, this machine produces core circulatory parameters continuously. Autonomic nervous function (BP variation, HR variation) and baroreflex sensitivity is also analysed.
Continuous measurement of peripheral oxygen saturation is registered with Masimo SET pulse oximeters.
13.4 Statistics
Responses with and without sildenafil will be compared within same individual. For parameters affected by calibration differences in machinery from test 1 to 2 delta values will be compared.
Power analysis:
Data from the main study allow estimations of anticipated results and statistical power. If the average of maximal RVSP during exercise in our group is 50 mmHg and sildenafil causes a 20% decrease in average to 40 mmHg (SD 10.0) a sample size of 13 patients leads to statistical power of 81.7% with 5% confidence level (calculation: DSS research 10.7.2008, http://www.dssresearch.com/toolkit/spcalc/power_a2.asp
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
Who may qualify
- Ages
- 16 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (2 listed)
- Exercise right ventricular systolic pressure of 45 mm Hg or above.
- Operated for atrial septal defect or ventricular septal defect or minimal defect not operated or minimal residual defect.
Key exclusion criteria (2 listed)
- Acute infectious/febrile illness,
- Significant mental or physical disability preventing reliable exercise testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sildenafil citratecapsule of 50 mg , 90 minutes before exercise study | Drug | – |
Primary outcome
Right ventricular pressure as measured by max velocity of tricuspid valve regurgitation
Time frame: baseline and max exercise
2 secondary outcomes
DLco (lung diffusion test)
Time frame: baseline and max exercise
cardiac output
Time frame: baseline and max exercise
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2008.
Related trials for Congenital Heart Disease
Not yet recruiting
Autologous Thymus Transplant in Children With Congenital Heart Disease: A Pilot Study
Congenital Heart Disease (CHD)
RecruitingPhase 1
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
Friedreich's Ataxia (FA)
RecruitingObservational study
The CACHE Study: Coronary Artery Care in HaEmophilia
Haemophilia, Cardiovascular Diseases
RecruitingObservational study
Essen Amyloidosis Registry
Amyloidosis; Systemic, Amyloidosis Cardiac
RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Turner Syndrome, Short Stature Homeobox Gene Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing sildenafil citrate in people with Congenital Heart Disease, run by Oslo University Hospital at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Oct 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Erik Thaulow, professor Dr Med (+47 23074537, erik.thaulow@rikshospitalet.no), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Right ventricular pressure as measured by max velocity of tricuspid valve regurgitation (time frame: baseline and max exercise). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2008.